VivoSim's NAMkind Models Validated for Predicting ADC Toxicity and Side Effects
ByAinvest
Tuesday, Mar 24, 2026 8:06 am ET1min read
VIVS--
VivoSim Labs has validated its NAMkind liver and intestine models to predict toxicity and side effects of antibody drug conjugates (ADCs). The models have shown close correlation with clinical results and can help screen out toxicities during lead candidate optimization or earlier stages, potentially resulting in greater success in the clinic with limited side effect profiles. NAMkind liver and small intestine toxicology services are now available globally.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue



Comments
No comments yet